BioFluidica and our technology are highlighted as a "Feature Article" in the February 01, 2018, Vol. 38, No. 3, issue of Genetic Engineering & Biotechnology News.
Cancer metastasis causes 90% of all cancer-related deaths. Scientists agree that the metastases occur when cancer cells are shed from the primary tumor, carried by the peripheral blood, and deposited at a distal site to create a new colony. An ability to detect circulating tumor cells, CTCs, or cell-free cancer DNA, cfDNA, in blood or saliva opens possibilities to suspect cancer even before it is visible on radiological images.
BioFluidica is dedicated to commercialization of the microfluidic chips for liquid biopsy biomarkers on the oncology-related aspects of liquid biopsies. "Our goal is to develop a universal technology capable of isolating all three oncological markers: cell-free DNA, exosomes, and CTCs," says Dr. Soper with the University of Kansas, and the inventor of our technology. "But more importantly, the isolated material has to be fully compatible with downstream genetic analysis, which requires high purity isolates."